Purpose of this Study
We are doing this study to find out how an experimental vaccine (pING-hHER3FL) works in your body and against your cancer.
Who Can Participate?
Eligibility
People who:
- Have the one of the following cancers:
--Breast
--Colon
--Lung
--Prostate
--Ovarian
--Cervical
--Endometrial
--Gastric (stomach)
--Pancreatic
--Bladder
--Head and neck
--Liver
--Esophageal
- Have been treated with surgery and/or chemotherapy and radiation
For more information about who can join this study, please contact the study team at felecia.walton@duke.edu.
- Have the one of the following cancers:
--Breast
--Colon
--Lung
--Prostate
--Ovarian
--Cervical
--Endometrial
--Gastric (stomach)
--Pancreatic
--Bladder
--Head and neck
--Liver
--Esophageal
- Have been treated with surgery and/or chemotherapy and radiation
For more information about who can join this study, please contact the study team at felecia.walton@duke.edu.
What is Involved?
If you choose to do this study, you will:
- Get the study vaccine three times over 8 weeks
- Have occasional blood draws for 5 years
- Have a biopsy to collect tumor tissue, if necessary
- Get the study vaccine three times over 8 weeks
- Have occasional blood draws for 5 years
- Have a biopsy to collect tumor tissue, if necessary
Study Details
Full Title
ASSESSING THE IMMUNOGENICITY OF pING-hHER3FL VACCINE IN PATIENTS WITH RESECTED MALIGNANCIES
Principal Investigator
Michael
Morse
Protocol Number
PRO00104093
NCT ID
NCT03832855
Phase
I
Enrollment Status
OPEN TO ACCRUAL